# Health Plans are Now Covering New Weight Loss Drugs. This Can Help Fix the Obesity Epidemic

By Kevin Stevenson · Published 2024-04-05 · Updated 2026-05-19 · Healthcare on MarketScale
Canonical: https://www.marketscale.com/industries/healthcare/health-plans-covering-new-weight-loss-drugs-obesity-epidemic-solution
Creator hub: I Don't Care

> Widespread insurance coverage of breakthrough weight loss medications could redirect billions in healthcare spending from treating obesity-related diseases to p

## Key points

- Over 42% of American adults are classified as obese, making coverage decisions for weight loss drugs a major policy and cost issue for health plans.
- New medications like Wegovy and Mounjaro show clinical promise but carry high price tags that complicate insurance coverage decisions.
- Health plans are being encouraged to reframe obesity as a chronic, long-term condition requiring sustained treatment rather than episodic intervention.

Block Field

In recent years, the [obesity epidemic](https://www.who.int/activities/controlling-the-global-obesity-epidemic) in the United States has reached alarming proportions, with more than [42% of American adults considered obese](https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity). This surge in obesity rates has sparked a significant conversation about the role of health plans in covering new weight loss drugs. As [healthcare costs continue to rise](https://marketscale.com/industries/healthcare/executive-order-healthcare-pricing/), the question of how these treatments fit into the broader strategy for managing obesity and related health conditions has become more pressing.

> With more than 42% of American adults considered obese, the obesity epidemic in the United States has reached alarming proportions.

In the latest episode of [I Don’t Care](https://marketscale.com/shows/i-dont-care/), host Dr. Kevin Stevenson delves into the role of health plans in covering new weight loss drugs with [**Dr. Nancy Klotz**](https://www.linkedin.com/in/nancy-klotz-md-mba-facp-121b2591/), Chief Medical Officer at [**Brighton Health Plan Solutions**](https://brightonhps.com/). The discussion centers around the challenges and opportunities presented by new FDA-approved weight loss medications and their implications for healthcare plans and patients.

Key Points from the episode:

– The obesity epidemic in the U.S. is worsening, with a significant portion of the population affected by obesity-related health conditions.

– New weight loss drugs like Wegovy and Mounjaro have shown promise in treating obesity, but their high cost raises questions about insurance coverage.

– Health plans are encouraged to approach obesity as a chronic disease requiring long-term treatment and maintenance.

> Health plans are encouraged to approach obesity as a chronic disease requiring long-term treatment and maintenance.

### About the Guest

**Dr. Nancy Klotz** is a seasoned internist with over 30 years of experience in medical management. As the Chief Medical Officer at **Brighton Health Plan Solutions**, she oversees medical benefits, plan design, and various health and wellness programs.

Tags: Brighton Health Plan Solutions, Dr. Kevin Stevenson, Dr. Nancy Klotz, I Don't Care with Kevin Stevenson, obesity epidemic

---
Source: MarketScale, https://www.marketscale.com/industries/healthcare/health-plans-covering-new-weight-loss-drugs-obesity-epidemic-solution. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt